What is Altris?
Altris is a pioneering medical technology firm dedicated to optimizing the diagnostic process for ophthalmologists and optometrists. The company specializes in the automation of optical coherence tomography (OCT) scan selection, a critical component in identifying ocular pathologies. By integrating sophisticated artificial intelligence, Altris enables clinicians to perform examinations with greater speed and accuracy, effectively mitigating the risk of overlooking rare or early-stage conditions.
The platform serves as a robust clinical decision support system, providing practitioners with a reliable second opinion when evaluating complex or controversial OCT imagery. By streamlining these diagnostic workflows, Altris addresses the persistent challenge of high patient volumes and the need for diagnostic consistency in modern eye care facilities. Its market position is defined by its ability to bridge the gap between raw imaging data and actionable clinical insights.
How much funding has Altris raised?
Altris has raised a total of $1M across 1 funding round:
Other Financing Round
$1M
Other Financing Round (2022): $1M with participation from Runa Capital and Artesian Group
Key Investors in Altris
Runa Capital
Runa Capital is an international venture capital firm that invests in deep tech and software, with a strong track record of supporting over 80 companies across Europe and North America.
Artesian Group
Artesian Group is a diversified development firm with expertise in construction and design, providing strategic backing to innovative ventures.
What's next for Altris?
With the recent influx of capital, Altris is poised to expand its footprint within the global healthcare market. The strategic roadmap likely involves scaling its software-as-a-service (SaaS) infrastructure to support larger hospital networks and multi-site clinical practices. Furthermore, the company is expected to invest heavily in research and development to broaden its diagnostic algorithms, potentially covering a wider spectrum of retinal and ocular diseases.
As the firm matures, the focus will shift toward regulatory expansion and deeper integration with existing electronic health record (EHR) systems. By solidifying its role as an essential partner in the diagnostic ecosystem, Altris is well-positioned to capitalize on the increasing demand for AI-augmented healthcare solutions, ultimately setting a new standard for efficiency and diagnostic precision in the field of ophthalmology.
